Isabelle Ray‐Coquard

43.4k total citations · 9 hit papers
418 papers, 16.7k citations indexed

About

Isabelle Ray‐Coquard is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Isabelle Ray‐Coquard has authored 418 papers receiving a total of 16.7k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Oncology, 167 papers in Reproductive Medicine and 132 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Isabelle Ray‐Coquard's work include Ovarian cancer diagnosis and treatment (161 papers), Sarcoma Diagnosis and Treatment (77 papers) and PARP inhibition in cancer therapy (58 papers). Isabelle Ray‐Coquard is often cited by papers focused on Ovarian cancer diagnosis and treatment (161 papers), Sarcoma Diagnosis and Treatment (77 papers) and PARP inhibition in cancer therapy (58 papers). Isabelle Ray‐Coquard collaborates with scholars based in France, United States and Italy. Isabelle Ray‐Coquard's co-authors include Jean‐Yves Blay, Philipp Harter, Alexander Reuß, Andreas du Bois, Éric Pujade-Lauraine, Jacobus Pfisterer, Ana Oaknin, Eric Pujade‐Lauraine, Thomas Bachelot and Christine Ménétrier‐Caux and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Isabelle Ray‐Coquard

398 papers receiving 16.4k citations

Hit Papers

Role of surgical outcome ... 2005 2026 2012 2019 2009 2014 2009 2009 2005 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
    2009 1.1k citations Alexander Reuß, Isabelle Ray‐Coquard et al. Cancer profile →
  2. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
    2014 1.1k citations Éric Pujade-Lauraine, Felix Hilpert et al. Journal of Clinical Oncology profile →
  3. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
    2009 624 citations Isabelle Ray‐Coquard, Axel Le Cesne et al. Cancer Research profile →
  4. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
    2009 562 citations Michael Gobert, Isabelle Treilleux et al. Cancer Research profile →
  5. Consensus meeting for the management of gastrointestinal stromal tumors
 Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO
    2005 561 citations Jean‐Yves Blay, Sylvie Bonvalot et al. profile →
  6. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
    2012 539 citations Thomas Bachelot, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
  7. Endometrial cancer
    2021 340 citations Vicky Makker, Helen Mackay et al. profile →
  8. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
    2020 261 citations Isabelle Ray‐Coquard et al. profile →
  9. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2023 149 citations Antonio González-Martı́n, Domenica Lorusso et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabelle Ray‐Coquard France 64 7.0k 5.5k 5.1k 3.6k 2.8k 418 16.7k
Allan T. van Oosterom Belgium 32 9.3k 1.3× 10.1k 1.9× 962 0.2× 4.3k 1.2× 4.5k 1.6× 89 21.9k
Martee L. Hensley United States 55 4.2k 0.6× 4.7k 0.9× 3.8k 0.7× 1.6k 0.4× 1.8k 0.6× 223 13.3k
Patrick Therasse Belgium 23 10.9k 1.6× 8.6k 1.6× 883 0.2× 3.2k 0.9× 3.6k 1.3× 36 20.5k
J. Wanders Netherlands 38 11.1k 1.6× 7.9k 1.5× 906 0.2× 3.0k 0.8× 4.2k 1.5× 132 19.6k
Suzanne George United States 55 3.7k 0.5× 6.8k 1.3× 541 0.1× 2.1k 0.6× 1.8k 0.6× 257 11.7k
Andrés Cervantes Spain 68 18.1k 2.6× 9.4k 1.7× 961 0.2× 8.4k 2.3× 4.2k 1.5× 468 27.8k
Marianna Zahurak United States 69 6.8k 1.0× 5.0k 0.9× 742 0.1× 5.7k 1.6× 3.5k 1.2× 221 16.8k
Robert A. Soslow United States 85 4.3k 0.6× 4.5k 0.8× 10.4k 2.0× 3.3k 0.9× 4.8k 1.7× 426 23.6k
Antoîne Italiano France 67 9.0k 1.3× 9.2k 1.7× 377 0.1× 2.6k 0.7× 4.0k 1.4× 618 17.5k
Irene Floriani Italy 47 3.3k 0.5× 2.3k 0.4× 1.4k 0.3× 1.8k 0.5× 1.2k 0.4× 159 8.3k

Countries citing papers authored by Isabelle Ray‐Coquard

Since Specialization
Citations

This map shows the geographic impact of Isabelle Ray‐Coquard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Ray‐Coquard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Ray‐Coquard more than expected).

Fields of papers citing papers by Isabelle Ray‐Coquard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Ray‐Coquard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Ray‐Coquard. The network helps show where Isabelle Ray‐Coquard may publish in the future.

Co-authorship network of co-authors of Isabelle Ray‐Coquard

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Ray‐Coquard. A scholar is included among the top collaborators of Isabelle Ray‐Coquard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Ray‐Coquard. Isabelle Ray‐Coquard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosso, Roberta, Fulvio Borella, Nicolás Chopin, et al.. (2025). Ovarian clear cell carcinoma: open questions on the management and treatment algorithm. The Oncologist. 30(1). 5 indexed citations
2.
Maillet, Denis, Thomas Bochaton, François Delahaye, et al.. (2024). Recommandations de dépistage en France : une revue systématique. Santé Publique. vol. 36(5). 15–35. 1 indexed citations
3.
Collet, L., Pierre Méeus, Nicolás Chopin, et al.. (2023). Gynecological carcinosarcomas: Overview and future perspectives. Bulletin du Cancer. 110(11). 1215–1226.
4.
Karabajakian, Andy, Catherine Genestie, Pierre Méeus, et al.. (2023). Adénosarcomes mullériens de l’utérus – référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG. Bulletin du Cancer. 110(7-8). 836–843. 2 indexed citations
5.
Ray‐Coquard, Isabelle, Jean‐Yves Blay, Armelle Dufresne, et al.. (2023). Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection. The Oncologist. 28(7). 633–639. 5 indexed citations
6.
Vergote, Ignace, Isabelle Ray‐Coquard, Domenica Lorusso, et al.. (2023). Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?. Expert Opinion on Investigational Drugs. 32(3). 201–211. 5 indexed citations
7.
Karabajakian, Andy, Isabelle Ray‐Coquard, & Jean‐Yves Blay. (2022). Molecular Mechanisms of Kaposi Sarcoma Development. Cancers. 14(8). 1869–1869. 12 indexed citations
8.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102. 1 indexed citations
9.
Leman, Raphaël, Étienne Muller, Nicolas Goardon, et al.. (2022). 2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers. International Journal of Gynecological Cancer. 32. A280–A280. 1 indexed citations
10.
Amadéo, Brice, Nicolas Penel, Jean‐Michel Coindre, et al.. (2022). Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM). Cancer. 128(13). 2483–2492. 7 indexed citations
11.
Nassif, Elise F., Édouard Auclin, Rastilav Bahleda, et al.. (2021). TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers. 13(13). 3362–3362. 7 indexed citations
12.
Ray‐Coquard, Isabelle, et al.. (2014). Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer. Clinical Breast Cancer. 15(1). 60–65. 27 indexed citations
13.
Woźniak, Agnieszka, Piotr Rutkowski, Patrick Schöffski, et al.. (2014). Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research. 20(23). 6105–6116. 121 indexed citations
14.
Pujade-Lauraine, Éric, Felix Hilpert, B. Weber, et al.. (2014). Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. Journal of Clinical Oncology. 32(13). 1302–1308. 1117 indexed citations breakdown →
15.
Herzog, Thomas J., Giovanni Scambia, Byoung‐Gie Kim, et al.. (2013). A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecologic Oncology. 130(1). 25–30. 69 indexed citations
16.
Ray‐Coquard, Isabelle, Antoîne Italiano, Emmanuelle Bompas, et al.. (2012). Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). The Oncologist. 17(2). 260–266. 148 indexed citations
17.
Duffaud, Florence, Caroline Even, Isabelle Ray‐Coquard, et al.. (2012). Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. SHILAP Revista de lepidopterología. 2(1). 11–11. 2 indexed citations
18.
Labidi‐Galy, Sana Intidhar, Vanja Sisirak, Pierre Méeus, et al.. (2011). Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. Cancer Research. 71(16). 5423–5434. 187 indexed citations
19.
Gobert, Michael, Isabelle Treilleux, Nathalie Bendriss‐Vermare, et al.. (2009). Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Research. 69(5). 2000–2009. 562 indexed citations breakdown →
20.
Guastalla, Jean‐Paul, Thomas Bachelot, & Isabelle Ray‐Coquard. (2004). Cyclo‐oxygénase 2 et cancer du sein. Des concepts biologiques aux essais thérapeutiques. Bulletin du Cancer. 91(1). 99–108. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Allan T. van Oosterom Breakdown of academic impact, for papers by Martee L. Hensley Breakdown of academic impact, for papers by Patrick Therasse Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Suzanne George Breakdown of academic impact, for papers by Andrés Cervantes Breakdown of academic impact, for papers by Marianna Zahurak Breakdown of academic impact, for papers by Robert A. Soslow Breakdown of academic impact, for papers by Antoîne Italiano Breakdown of academic impact, for papers by Irene Floriani
Rankless by CCL
2026